Sort   by:  
 Page size 
GenomicsThe mitochondrial protease LonP1 promotes proteasome inhibitor resistance in multiple myeloma.
The mitochondrial protease LonP1 promotes proteasome inhibitor resistance in multiple myeloma.
PRJNA699295 | ENA
TranscriptomicsBortezomib resistance in THP-1 cell line
Bortezomib is a proteasome inhibitor used in severel different hematological malignancies. Resistance to this drug is still poorly understood. In order get more insight in the resistance mechanism, we developed several bortezomib resistant subclones of the THP-1 monocytic/macrophage cell line. On th...
ORGANISM(S): Homo sapiens 
2008-06-14 | E-GEOD-11771 | biostudies-arrayexpress
GenomicsAllosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma
Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma
PRJNA625299 | ENA
TranscriptomicsGenome-wide analysis of gene expression in response to bortezomib treatment [mouse cell lines II]
Genome-wide analysis of gene expression in response to bortezomib treatment(33 nM) in cell lines before and after selection for resistance. Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of neoplastic plasma cells in the bone marrow. While the first-to-market pr...
ORGANISM(S): Mus musculus 
2013-07-02 | E-GEOD-41928 | biostudies-arrayexpress
TranscriptomicsGenome-wide analysis of gene expression in response to bortezomib treatment [mouse cell lines I]
Genome-wide analysis of gene expression in response to bortezomib treatment (33 nM) in cell lines before and after selection for resistance. Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of neoplastic plasma cells in the bone marrow. While the first-to-market p...
ORGANISM(S): Mus musculus 
2013-07-02 | E-GEOD-41927 | biostudies-arrayexpress
TranscriptomicsGenome-wide analysis of gene expression in response to bortezomib treatment [human cell lines].
Genome-wide analysis of gene expression in response to bortezomib treatment (33 nM) in cell lines before and after selection for resistance. Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of neoplastic plasma cells in the bone marrow. While the first-to-market p...
ORGANISM(S): Homo sapiens 
2013-07-02 | E-GEOD-41929 | biostudies-arrayexpress
ProteomicsDeep Proteomic and Phosphoproteomic Profiling in Proteasome Inhibitor-Resistant Multiple Myeloma
Proteasome inhibitors (PIs) are frontline therapies for multiple myeloma (MM). Although MM patients initially respond to PIs, resistance frequently emerges. While clinical PIs primarily target the same proteasomal catalytic subunit (PSMB5), the extent to which resistance mechanisms are shared among ...
ORGANISM(S): Homo sapiens (Human) 
2026-07-15 | PXD077254 | Pride
Phosphoproteomics Proteasome inhibitor resistance Quantitative proteomics Multiple myeloma 
GenomicsRibosomal protein S3 mediates drug resistance of proteasome inhibitor: therapeutic application in multiple myeloma
Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: therapeutic application in multiple myeloma
PRJNA1005973 | ENA
TranscriptomicsTight Junction Protein 1 is a Modulator and Biomarker of Proteasome Inhibitor Sensitivity in Multiple Myeloma
Proteasome inhibitors are important chemotherapeutics in the treatment of multiple myeloma, but they are currently used empirically as no markers of sensitivity have been validated. We have identified expression of tight junction protein (TJP) 1 as being associated with sensitivity of plasma cells ...
ORGANISM(S): Homo sapiens 
2015-12-31 | E-GEOD-52369 | biostudies-arrayexpress
ProteomicsTargeting ubiquitin-independent proteasome with small molecule increases susceptibility in pan-KRAS mutant cancers
Despite advances in the development of direct KRAS inhibitors, KRAS-mutant cancers continue to exhibit resistance to the currently available therapies. Here, we identified REGγ as a mutant KRAS-associated factor that enhances REGγ transcription through the KRAS intermediate NRF2, suggesting that the...
ORGANISM(S): Homo Sapiens 
2025-01-01 | PXD059364 |
Sort   by:  
 Page size